Sarepta's High-Stakes Data to Shape Future of Duchenne Treatment

CAMBRIDGE, Mass. – February 26, 2026

The world of genetic medicine is poised for a pivotal moment as Sarepta Therapeutics prepares to unveil a trove of long-term data for its Duchenne muscular dystrophy (DMD) portfolio at the upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Congress. The presentations, scheduled for March 8-11 in Orlando, Florida, represent a critical juncture for the company, the clinicians who prescribe its therapies, and the families who depend on them. At stake is the long-term validation of its pioneering gene therapy, ELEVIDYS, and the future of its exon-skipping franchise, which faces a crucial test following a challenging clinical trial readout.

For years, Sarepta has been at the forefront of the fight against Duchenne, a devastating and progressive muscle-wasting disease. Now, the company aims to solidify its leadership by presenting a comprehensive picture of its treatments' performance over several years, moving beyond initial efficacy signals to demonstrate durability, safety, and real-world impact.

The Gene Therapy Spotlight: ELEVIDYS's Long-Term Promise

All eyes will be on the late-breaking oral presentation for delandistrogene moxeparvovec, marketed as ELEVIDYS. The company will present functional outcomes and safety data from the Phase 3 EMBARK study extending up to three years post-infusion. This follows promising two-year results published in January that showed statistically significant benefits in key functional measures compared to an external control group, suggesting the therapy can meaningfully slow disease progression.

ELEVIDYS made history as the first gene therapy approved for DMD, receiving an expanded FDA approval in June 2024 for both ambulatory and non-ambulatory patients aged four and older. The upcoming three-year data is essential for reinforcing its value proposition, particularly given its $3.2 million price tag. A consistent and durable effect over time would cement its status as a foundational, one-time treatment for the disease.

Further bolstering the case will be a separate pooled safety analysis from clinical trials with up to 7.5 years of patient follow-up. Long-term safety is a paramount concern for all gene therapies, which use a viral vector to deliver their genetic payload. Demonstrating a manageable and predictable safety profile over many years is crucial for clinician and patient confidence, especially as Sarepta faces competition from companies like Pfizer, which is developing its own DMD gene therapy.

“At MDA we’re sharing data that reinforce dystrophin restoration as a foundational therapy and its ability to slow Duchenne disease progression over time,” said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations at Sarepta, in a statement. The company's goal is to provide a complete, data-driven view to help families and doctors “make treatment decisions with confidence.”

A Critical Test for Exon-Skipping Therapies

While ELEVIDYS represents the new frontier, the conference will also be a proving ground for Sarepta's established exon-skipping therapies. The company will present the full Phase 3 results from its ESSENCE study for golodirsen (VYONDYS 53) and casimersen (AMONDYS 45). These drugs received accelerated approval from the FDA based on their ability to increase dystrophin protein production, but that approval was contingent on proving a clinical benefit in a confirmatory trial like ESSENCE.

The stakes for this presentation are exceptionally high. In November 2025, Sarepta announced that the ESSENCE study did not meet its primary endpoint, a measure of how quickly patients could ascend four steps. This result cast a shadow over the therapies' long-term commercial and regulatory future.

Now, the medical community and regulators will be scrutinizing the full dataset for any signs of clinical benefit. Analysts will be parsing secondary endpoints, subgroup analyses, and safety data to determine if there is a path forward. A strong showing on other functional measures could still make a compelling case for their value in a disease with no cure. Conversely, a lack of convincing data could pose significant challenges.

Providing a potential lifeline is the growing body of real-world evidence for the exon-skipping class. Sarepta will also present interim findings from its Phase 4 EVOLVE study, which tracks patients on its exon-skipping drugs in routine clinical practice. Previous data from this study on eteplirsen (EXONDYS 51), the first approved drug for DMD, showed it significantly delayed the loss of ambulation and slowed cardiac decline—powerful evidence of its real-world impact that may offer a hopeful narrative for the entire franchise.

Beyond the Data: Real-World Impact and Patient Perspectives

Moving beyond traditional clinical endpoints, Sarepta's presentations signal a broader effort to capture the full impact of its treatments on patients' lives. A key poster will feature caregiver-reported impressions from the EMBARK study, offering a complementary perspective on how a treatment affects daily life, function, and family well-being—factors that a stopwatch in a clinic cannot always measure.

For a relentlessly progressive disease like Duchenne, the definition of success is often nuanced. Slowing the decline, preserving function for longer, and maintaining quality of life are monumental victories for patients and their families. This is a perspective consistently championed by patient advocacy groups, who have been instrumental in pushing for access to novel therapies.

The real-world analyses on survival and loss of ambulation for patients treated with exon-skipping medicines further underscore this point. This data provides a crucial long-term view that helps contextualize the results from controlled, and often brief, clinical trials. For families facing a devastating diagnosis, evidence that a therapy can add years of mobility or delay cardiac complications is profoundly meaningful.

Navigating a Shifting Market and Scientific Landscape

The data unveiled at MDA 2026 will not exist in a vacuum. It will land in a dynamic and competitive landscape where Sarepta is working to defend its leadership against other large pharmaceutical players and nimble biotechs exploring next-generation technologies like CRISPR-based gene editing. Strong, long-term data for ELEVIDYS is Sarepta’s best defense, creating a high bar for any new entrants.

For investors, the conference represents a moment of reckoning. Positive, durable data for ELEVIDYS could solidify its blockbuster potential and drive significant growth for the company. The fate of the exon-skipping franchise, however, remains a key variable. The full ESSENCE results will heavily influence the future revenue trajectory of VYONDYS 53 and AMONDYS 45 and could impact regulatory reviews worldwide.

Ultimately, the coming presentations are about more than just stock prices and market share. They represent the culmination of years of research and the hopes of an entire community. The data will provide the clearest picture yet of the long-term promise of genetic medicine for Duchenne muscular dystrophy, shaping the standard of care and influencing treatment decisions for thousands of patients for years to come.